Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Active not recruiting 7Recruiting 6Completed 5Terminated 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Prostatic Neoplasms 4Burkitt Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hormone-Resistant Prostate Cancer 1Hematologic Neoplasms 1

Interventions

Rituximab 30Cyclophosphamide 25Filgrastim 19Methotrexate 15fludarabine phosphate 13Etoposide 13Cytarabine 13Peripheral Blood Stem Cell Transplantation 12Cyclosporine 11Vincristine 10Mycophenolic Acid 10Whole-Body Irradiation 9Antilymphocyte Serum 9Radiotherapy 8Granulocyte Colony-Stimulating Factor 8CT-P10 8fludarabine 7Prednisone 7Doxorubicin 7Dexamethasone 7merphos 6Tacrolimus 6Melphalan 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5deltacortene 5auricularum 5Methylprednisolone 5Leucovorin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Burkitt Lymphoma × prednylidene × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02420717 2025-06-08

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled 13 charts
Lymphoid

Burkitt Lymphoma

NCT03488225 2024-07-16

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled 11 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡